百花医药
(600721)
| 流通市值：34.30亿 | | | 总市值：34.30亿 |
| 流通股本：3.85亿 | | | 总股本：3.85亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 298,606,173.49 | 202,086,632.21 | 96,917,183.06 | 385,755,767.94 |
| 营业收入 | 298,606,173.49 | 202,086,632.21 | 96,917,183.06 | 385,755,767.94 |
| 二、营业总成本 | 225,319,472.13 | 151,013,949.71 | 69,790,602.6 | 293,053,303.13 |
| 营业成本 | 151,815,043.58 | 102,255,288.25 | 47,091,129.13 | 188,295,698.19 |
| 税金及附加 | 3,682,947.99 | 2,458,486.14 | 1,149,557.77 | 5,216,353.99 |
| 销售费用 | 10,113,891.22 | 6,667,951.75 | 2,430,443.29 | 11,368,492.51 |
| 管理费用 | 42,443,518.83 | 28,027,840.35 | 13,236,147.26 | 60,025,107.05 |
| 研发费用 | 18,076,939.87 | 12,168,211.14 | 6,183,247.17 | 29,547,683.22 |
| 财务费用 | -812,869.36 | -563,827.92 | -299,922.02 | -1,400,031.83 |
| 其中:利息收入 | 855,946.7 | 593,081.39 | 317,961.66 | 1,465,140.38 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | -125,000 |
| 加:投资收益 | 2,138,241.16 | 1,566,645.02 | 630,163.75 | 3,495,093.54 |
| 资产处置收益 | - | - | - | 89,534.43 |
| 资产减值损失(新) | -27,488,316.82 | -14,586,352.55 | -2,144,716.44 | -43,455,839.69 |
| 信用减值损失(新) | -10,047,140.26 | -7,901,776.69 | -4,041,106.78 | -17,048,933.98 |
| 其他收益 | 997,728.85 | 497,882.1 | 369,448.68 | 1,378,422.55 |
| 四、营业利润 | 38,887,214.29 | 30,649,080.38 | 21,940,369.67 | 37,035,741.66 |
| 加:营业外收入 | 43,255.17 | 23,772.75 | 3,863.15 | 175,456.6 |
| 减:营业外支出 | 210,441.91 | 122,299.33 | 52,708.29 | 346,613.62 |
| 五、利润总额 | 38,720,027.55 | 30,550,553.8 | 21,891,524.53 | 36,864,584.64 |
| 减:所得税费用 | 6,045,796.48 | 5,067,147.95 | 1,170,664.59 | -4,614,458.4 |
| 六、净利润 | 32,674,231.07 | 25,483,405.85 | 20,720,859.94 | 41,479,043.04 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 32,674,231.07 | 25,483,405.85 | 20,720,859.94 | 41,479,043.04 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 32,674,231.07 | 25,483,405.85 | 20,720,859.94 | 41,479,043.04 |
| 扣除非经常损益后的净利润 | 30,420,688.49 | 24,058,720.87 | 20,069,492.89 | 29,652,763.33 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.07 | 0.05 | 0.11 |
| (二)稀释每股收益 | 0.09 | 0.07 | 0.05 | 0.11 |
| 八、其他综合收益 | - | - | - | -98,649.55 |
| 归属于母公司股东的其他综合收益 | - | - | - | -98,649.55 |
| 九、综合收益总额 | 32,674,231.07 | 25,483,405.85 | 20,720,859.94 | 41,380,393.49 |
| 归属于母公司股东的综合收益总额 | 32,674,231.07 | 25,483,405.85 | 20,720,859.94 | 41,380,393.49 |
| 公告日期 | 2025-10-28 | 2025-08-22 | 2025-04-26 | 2025-03-12 |
| 审计意见(境内) | | | | 标准无保留意见 |